MIMEDX Announces Favorable Ruling in Putative Securities Class Action Case

2 years ago

MARIETTA, Ga., July 11, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that…

Microbot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board

2 years ago

Believes that the reduction in radiation exposure the LIBERTY® system could empower more women to pursue careers in Interventional RadiologyHINGHAM,…

McClintock and Amfora Form Strategic Collaboration to Leverage AI to Improve Protein Content of Soy

2 years ago

SAN FRANCISCO, July 11, 2023 (GLOBE NEWSWIRE) -- Artificial intelligence and machine learning innovator McClintock LLC has entered into a…

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

2 years ago

HAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed…

SmileDirectClub Expands SmileShop Reach With Openings Across the US

2 years ago

Oral Care Leader Opens 18 New Locations Of Its Patented SmileShop Concept As It Celebrates Two Million Customers Served Through…

Teknova Expands Proprietary AAV-Tek™ Solutions Product Line to Deliver End-to-End Solutions for Gene Therapy Process Development

2 years ago

First-of-its-kind screening kit now available for AAV8 – along with a suite of high-quality reagents to support the entire AAV…

Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

2 years ago

Akari has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to move forward into clinical trials…

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

2 years ago

Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months of treatment with XPro1595TM Boca Raton, Florida,…

PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301

2 years ago

Composition of matter and use patent for Versamune® in combination with PDS0301 allowed in CanadaPDS Biotech’s proprietary combination of Versamune®…